OREANDA-NEWS. The Federal Antimonopoly Service (FAS Russia) issued a warning to TEVA PHARMACEUTICAL INDUSTRIES LIMITED of Israel to stop actions (omissions) that have signs of violating the antimonopoly law.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED avoided concluding a contract with “BIOTEK” MFPDK” CJSC for supplying an essential innovative medicine - Copaxone Teva and considering applications “BIOTEK” MFPDK” CJSC, which is a violation of Clause 5 Part 1 Article 10 of the Federal Law “On Protection of Competition”.

“Under an agreement between TEVA and “BIOTEK” MFPDK” CJSC , the latter is involved in the final stage of production, serial drug production, as well as its storage, sales and distribution in the Russian Federation.

Copaxone Teva is used for treating multiple sclerosis (a disease classified by law into a category of rare diseases) and has no analogues.

“This is already not the first warning issued by FAS to “BIOTEK” MFPDK” CJSC. Avoiding a contact leads to terminating “BOITEK” efforts of the medicine in the Russian Federation Copaxone Teva”, commented the Head of FAS Department for Social Sphere and Trade, Timophei Nizhegorodtsev.